시장보고서
상품코드
1309225

세계의 종양학 및 면역학 관련 유세포 분석 시장-산업 규모, 점유율, 동향, 경쟁, 기회, 예측(2018-2028년)

Flow Cytometry in Oncology and Immunology Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2018-2028 Segmented By Type, By Technology, By Offering, By Application, By End User, By Region

발행일: | 리서치사: TechSci Research | 페이지 정보: 영문 116 Pages | 배송안내 : 2-3일 (영업일 기준)


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 종양학 및 면역학 유동 세포 계측(Flow Cytometry in Oncology and Immunology) 시장은 예측 기간인 2024년부터 2028년까지 안정적인 성장이 예상됩니다.

연구활동에서 유동세포계측기 적용 범위가 확대되어 차세대 유동세포계측기 연구개발이 진행될 것으로 예상됩니다. 세계보건기구(WHO)에 따르면 암은 세계의 질병 부담과 사망률 주요 원인 중 하나이며, 암 예방, 진단 및 치료 전략은 여전히 세계적인 노력이 필요합니다. 종양학 및 면역학 유동 세포 계측법은 혈액, 골수 또는 기타 조직 샘플 세포 수, 살아있는 세포 비율, 세포 크기 및 모양과 같은 특정 특징, 세포 표면 항원과 같은 종양 마커 존재를 측정하는 실험 절차를 나타냅니다. 면역종양학(IO)은 암 면역계 기능을 연구하고 암과 싸우는 면역계 능력을 향상시키는 치료법을 개발하는 학문입니다. 그러나 새로운 종양학 및 면역학 기술/도구 수요가 증가하고 있으며, 이는 종양학 및 면역학 관련 유세포 분석 시장 성장을 가속할 것으로 예상됩니다. 게다가, 치료 중 및 치료 후 면역 반응을 모니터링하기 위한 특이적이고 민감한 도구를 찾는 기술 개발과 노력은 수년간 시장 성장을 가속할 것으로 예상됩니다.

암 환자 증가

세계적으로 암은 일반적인 사망 원인 중 하나입니다. 암 환자 세계의 증가는 아마 암 분자 진단 약물 시장 확대 요인일 전망입니다. 미국 암 협회에 따르면 2021년 미국 신규 암 이환 환자 수는 180만 명, 암 사망자 수는 60만 명입니다.

의료관계자는 암 예방과 치료를 돕기 위해 악성세포를 확대시킨 결과 치료법과 진단서비스를 창출하기 위한 연구개발을 강화하고 있습니다. 암 면역요법은 여러 종양형의 표준치료가 되고 있으며, 질병 재발을 줄이고 보다 나은 생존 환경을 제공합니다. 식품약국(FDA)에 의하면, 복수 암종 치료 효과를 평가하기 위해 조합 치료를 실시하며 신약 개발을 위한 메커니즘 분석을 얻기 위해 또는 임상 반응 면역학적 예측 인자를 확인하기 위해 면역학적, 종양학적 치료가 성공한 복수 임상시험이 실시됩니다. 따라서 이러한 치료 및 개발된 치료법은 종양학 및 면역학 관련 유세포 분석 시장 성장을 가속하는 요인이 되었습니다.

기술 진보

보다 정교한 기술 개발은 질량 세포 계측법, 이미징 흐름 세포 계측법, 게놈 세포 계측법, 스펙트럼 세포 계측법 등을 포함하며, 단일 세포 더 많은 세포 매개 변수를 동시에 높은 해상도로 특성화함으로써 면역 반응을 연구하는 능력을 확대하고 있습니다. 연구자에 따르면 면역계는 암세포를 표적으로 파괴할 수 있다고 합니다. 따라서 면역종양학에 기초한 치료에는 암 환자 면역반응을 높이기 위한 다양한 접근법이 포함됩니다. 이펙터 세포 활성화, 종양 항원 백신 접종, 종양 용해 바이러스 투여, 억제 경로나 면역억제 기구 차단, 입양 키메라 항원 수용체 T 세포 요법 사용, 방어 경로 증폭 등입니다.

최근 동향과 제품상시

종양학 및 면역학 관련 유세포 분석 시장은 주요 시장 플레이어 존재에 의해 목격됩니다. 예를 들어 2022년 6월, Becton, Dickinson, and Company사는 International Society for Advancement of Cytometry(ISAC) 새로운 세포 선별 기술을 발표했습니다. 2022년 9월, 벡톤 디킨슨은 면역학, 바이러스학, 암, 감염증 모니터링 등 다양한 분야 활약하는 연구자가 유세포 분석 프로세스를 개선하여 보다 양질 실험을 단시간에 이해할 수 있도록 설계된 클라우드 기반 소프트웨어 솔루션인 BD 조사 클라우드를 발표했습니다. 게다가 2022년 2월, 벡턴 디킨슨은 Cytognos, SL을 인수하고 유동세포계측기 포트폴리오를 확대하여 Cytognos SL 약 80명 과학자와 전문 지식을 획득했습니다.

사용 가능한 사용자 정의

TechSci Research는 주어진 시장 데이터를 사용하여 기업 고유 요구에 맞게 사용자 정의를 제공합니다. 보고서는 다음을 사용자 정의할 수 있습니다.

기업 정보

  • 추가 시장 진출기업(최대 5사) 상세 분석과 프로파일링

목차

제1장 주요 요약

제2장 조사 방법

제3장 주요 요약

제4장 고객 의견

제5장 종양학 및 면역학 관련 유세포 분석 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 유형별(면역학, 종양학)
    • 기술별(셀 베이스 플로우 사이토메트리, 비드 베이스 플로우 사이토메트리)
    • 제품별(시약, 장치, 소모품, 소프트웨어)
    • 용도별(트랜스레이셔널 리서치, 임상 연구)
    • 최종 사용자별(병원, 진단 랩, 레퍼런스 랩, 제약, 바이오테크놀로지 기업, 학술 연구 기관, 수탁 연구 기관, 기타)
    • 지역별(북미, 유럽, 아시아태평양, 남미, 중동 및 아프리카)
    • 기업별(2022년)
  • 시장 맵
    • 유형별
    • 기술별
    • 제품별
    • 용도별
    • 최종 사용자별
    • 지역별

제6장 북미 종양학 및 면역학 관련 유세포 분석 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 유형별
    • 기술별
    • 제품별
    • 용도별
    • 최종 사용자별
    • 국가별
  • 북미별 분석
    • 미국
    • 캐나다
    • 멕시코

제7장 유럽 종양학 및 면역학 유동 세포 계측 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 유형별
    • 기술별
    • 제품별
    • 용도별
    • 최종 사용자별
    • 국가별
  • 유럽 국가별 분석
    • 독일
    • 프랑스
    • 영국
    • 이탈리아
    • 스페인

제8장 아시아태평양 종양학 및 면역학 유동 세포 계측 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 유형별
    • 기술별
    • 제품별
    • 용도별
    • 최종 사용자별
    • 국가별
  • 아시아태평양 국가별 분석
    • 중국
    • 일본
    • 인도
    • 한국
    • 호주

제9장 남미 종양학 및 면역학 관련 유세포 분석 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 유형별
    • 기술별
    • 제품별
    • 용도별
    • 최종 사용자별
    • 국가별
  • 남미 : 국가별 분석
    • 브라질
    • 아르헨티나
    • 콜롬비아

제10장 중동 및 아프리카 종양학 및 면역학 관련 유세포 분석 시장 전망

  • 시장 규모 및 예측
    • 금액 기준
  • 시장 점유율과 예측
    • 유형별
    • 기술별
    • 제품별
    • 용도별
    • 최종 사용자별
    • 국가별
  • MEA : 국가별 분석
    • 아랍에미리트(UAE)
    • 사우디아라비아
    • 남아프리카
    • 터키
    • 이집트

제11장 시장 역학

  • 성장 촉진 요인
    • 암 환자 증가
    • 기술 진보
    • 최근 개발과 제품 상시
  • 과제
    • 플로우 사이토메트리 장치 제품의 높은 비용
    • 잘못된 항체 반응

제12장 시장 동향과 발전

제13장 경쟁 구도

  • Business Overview
  • Product Offerings
  • Recent Developments
  • Financials(As Reported)
  • Key Personnel
    • Danaher Corporation
    • Merck KGaA
    • Miltenyi Biotec
    • Neo-Genomics Laboratories, Inc.
    • Thermo Fisher Scientific Inc
    • Cell Signaling Technology, Inc
    • Becton, Dickinson and Company
    • Agilent Technologies, Inc.
    • DiaSorin SpA(Luminex Corporation)
    • OPKO Health, Inc.

제14장 전략 제안

NJH 23.08.30

Global Flow Cytometry in Oncology and Immunology Market is anticipated to witness a growth of steady CAGR in the forecast period, 2024-2028. This can be ascribed due to the expansion of flow cytometry's applicability in research activities and the development of next-generation flow cytometers. According to the World Health Organization, Cancer is one of the leading causes of disease burden and mortality in the world, and strategies for cancer prevention, diagnosis, and treatment are still a global effort. Flow cytometry in oncology and immunology refers to the laboratory procedure to measure the number of cells, the percentage of live cells, and certain characteristics of cells, such as size and shape, in a sample of blood, bone marrow, or other tissue, the presence of tumor markers, such as antigens, on the surface of the cells. Immuno-oncology (IO) is the study of the immune system's functionality against cancer and the development of treatments that improve the ability of the immune system to fight the disease. However, the demand for new oncology and immunologic techniques/tools is increasing, which is further expected to drive the growth of global flow cytometry in the oncology and immunology market. Additionally, the development of technology and efforts to find specific and sensitive tools to monitor immune responses during and after therapy is thereby expected to drive the growth of the market in the forecast years.

The growing prevalence of cancer cases, the technological advancement with the highest accuracy and precision, and the growing awareness amongst the population globally are projected to propel the growth of the market. However, the high cost of products of flow cytometry equipment is expected to hamper the growth of flow cytometry in the oncology and immunology market in the forecast years.

Rising Prevalence of Cancer Cases

Globally, Cancer is one of the prevalent causes of death. The global increase in cancer cases is probably a factor in the oncology molecular diagnostics market's expansion. In the United States of America in 2021, there were 1.8 million new cases and 0.6 million cancer deaths, according to the American Cancer Society.

Medical professionals are stepping up their research and development efforts to create therapies and diagnostic services as a result of the expansion of malignant cells to aid the prevention and treatment of cancer. Cancer immunotherapy is becoming the standard of care for multiple tumor types at diverse disease stages, providing better survival with reduced disease recurrences. According to Food and Drug Administration (FDA), multiple clinical trials with successful implementation of immunology and oncology treatments are being conducted to evaluate the efficacy of treatments of multiple cancer types, to implement combinatorial therapies, to gain mechanistic insight for new drug development or to identify immune predictors of clinical response. Therefore, their treatment and developed therapies are responsible for propelling the growth of global flow cytometry in the oncology and immunology market.

Advancement in Technology

The development of more advanced technologies includes mass cytometry, imaging flow cytometry, genomic cytometry, and spectral cytometry with an expanded ability to study immune responses by characterizing more cellular parameters simultaneously in single cells with higher resolution. According to the researchers, the immune system can target and destroy cancer cells; therefore, immune-oncology-based therapies cover different approaches to boost the immune response in cancer patients, that range from activation of effector cells, vaccination with tumor antigens, administration of oncolytic viruses, blockage of inhibitory pathways or immunosuppressive mechanisms, use of adoptive chimeric antigen receptor T-cell therapy, and to amplify the protective pathways.

Recent Developments & Product Launches

The growth of global flow cytometry in the oncology and immunology market is witnessed due to the presence of major market players. For instance, in June 2022, Becton, Dickinson, and Company launched its new cell sorting technology at the International Society for Advancement of Cytometry (ISAC). In September 2022, a company, namely Becton, Dickinson, launched BD Research Cloud, a cloud-based software solution designed to improve the flow cytometry process for researchers working in a variety of fields, such as immunology, virology, cancer, and infectious disease monitoring, in order to enable higher-quality experiments with faster time to understand. Additionally, in February 2022, Becton, Dickinson acquired Cytognos, S.L. and expanded its flow cytometry portfolio, and gained the expertise of ~80 scientists and professionals at Cytognos S.L.

Market Segmentation

Global Flow Cytometry in Oncology and Immunology Market can be segmented by type, technology, offering, application, end user, region, and company. Based on type, the market can be segmented into immunology and oncology. Based on technology, the market is fragmented into cell-based flow cytometry and bead-based flow cytometry. Based on the offering, the market is segmented into reagents, instruments, and consumables software. Based on application, the market is fragmented into translational research and clinical research. Based on end users, the market is segmented into hospitals, diagnostic laboratories, reference laboratories, pharmaceutical and biotechnology companies, academic research institutes, contract research organizations, and others.

Company Profiles

Danaher Corporation, Merck KGaA, Miltenyi Biotec, Neo-Genomics Laboratories, Inc., Thermo Fisher Scientific Inc., Cell Signaling Technology, Inc., Becton, Dickinson and Company, Agilent Technologies, Inc., DiaSorin S.p.A (Luminex Corporation), OPKO Health, Inc., etc., are some of the key players operating in the global flow cytometry in the oncology and immunology market.

Report Scope

In this report, Global Flow Cytometry in Oncology and Immunology Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Flow Cytometry in Oncology and Immunology Market, By Type:

  • Immunology
  • Oncology

Flow Cytometry in Oncology and Immunology Market, By Technology:

  • Cell-based flow cytometry
  • Bead-based flow cytometry

Flow Cytometry in Oncology and Immunology Market, By Offering:

  • Reagents
  • Instruments
  • Consumables software

Flow Cytometry in Oncology and Immunology Market, By Application:

  • Translational Research
  • Clinical Research

Flow Cytometry in Oncology and Immunology Market, By End User:

  • Hospitals
  • Diagnostic Laboratories
  • Reference Laboratories
  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes
  • Contract Research Organizations
  • Others

Flow Cytometry in Oncology and Immunology Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • South Africa
    • Turkey
    • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Flow Cytometry in Oncology and Immunology Market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Flow Cytometry in Oncology and Immunology Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Immunology, Oncology)
    • 5.2.2. By Technology (Cell-based flow cytometry, Bead-based flow cytometry)
    • 5.2.3. By Offering (Reagents, Instruments, and Consumables Software)
    • 5.2.4. By Application (Translational Research, Clinical Research)
    • 5.2.5. By End User (Hospitals, Diagnostic Laboratories, and Reference Laboratories, Pharmaceutical and Biotechnology Companies, Academic Research Institutes, Contract Research Organizations, and Others)
    • 5.2.6. By Region (North America, Europe, Asia Pacific, South America, Middle East and Africa)
    • 5.2.7. By Company (2022)
  • 5.3. Market Map
    • 5.3.1. By Type
    • 5.3.2. By Technology
    • 5.3.3. By Offering
    • 5.3.4. By Application
    • 5.3.5. By End User
    • 5.3.6. By Region

6. North America Flow Cytometry in Oncology and Immunology Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Technology
    • 6.2.3. By Offering
    • 6.2.4. By Application
    • 6.2.5. By End User
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Flow Cytometry in Oncology and Immunology Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By Offering
        • 6.3.1.2.4. By Application
        • 6.3.1.2.5. By End User
    • 6.3.2. Canada Flow Cytometry in Oncology and Immunology Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By Offering
        • 6.3.2.2.4. By Application
        • 6.3.2.2.5. By End User
    • 6.3.3. Mexico Flow Cytometry in Oncology and Immunology Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By Offering
        • 6.3.3.2.4. By Application
        • 6.3.3.2.5. By End User

7. Europe Flow Cytometry in Oncology and Immunology Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Technology
    • 7.2.3. By Offering
    • 7.2.4. By Application
    • 7.2.5. By End User
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Flow Cytometry in Oncology and Immunology Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By Offering
        • 7.3.1.2.4. By Application
        • 7.3.1.2.5. By End User
    • 7.3.2. France Flow Cytometry in Oncology and Immunology Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By Offering
        • 7.3.2.2.4. By Application
        • 7.3.2.2.5. By End User
    • 7.3.3. United Kingdom Flow Cytometry in Oncology and Immunology Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By Offering
        • 7.3.3.2.4. By Application
        • 7.3.3.2.5. By End User
    • 7.3.4. Italy Flow Cytometry in Oncology and Immunology Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Technology
        • 7.3.4.2.3. By Offering
        • 7.3.4.2.4. By Application
        • 7.3.4.2.5. By End User
    • 7.3.5. Spain Flow Cytometry in Oncology and Immunology Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Technology
        • 7.3.5.2.3. By Offering
        • 7.3.5.2.4. By Application
        • 7.3.5.2.5. By End User

8. Asia-Pacific Flow Cytometry in Oncology and Immunology Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Technology
    • 8.2.3. By Offering
    • 8.2.4. By Application
    • 8.2.5. By End User
    • 8.2.6. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Flow Cytometry in Oncology and Immunology Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By Offering
        • 8.3.1.2.4. By Application
        • 8.3.1.2.5. By End User
    • 8.3.2. Japan Flow Cytometry in Oncology and Immunology Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By Offering
        • 8.3.2.2.4. By Application
        • 8.3.2.2.5. By End User
    • 8.3.3. India Flow Cytometry in Oncology and Immunology Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By Offering
        • 8.3.3.2.4. By Application
        • 8.3.3.2.5. By End User
    • 8.3.4. South Korea Flow Cytometry in Oncology and Immunology Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By Offering
        • 8.3.4.2.4. By Application
        • 8.3.4.2.5. By End User
    • 8.3.5. Australia Flow Cytometry in Oncology and Immunology Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By Offering
        • 8.3.5.2.4. By Application
        • 8.3.5.2.5. By End User

9. South America Flow Cytometry in Oncology and Immunology Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Technology
    • 9.2.3. By Offering
    • 9.2.4. By Application
    • 9.2.5. By End User
    • 9.2.6. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Flow Cytometry in Oncology and Immunology Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By Offering
        • 9.3.1.2.4. By Application
        • 9.3.1.2.5. By End User
    • 9.3.2. Argentina Flow Cytometry in Oncology and Immunology Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By Offering
        • 9.3.2.2.4. By Application
        • 9.3.2.2.5. By End User
    • 9.3.3. Colombia Flow Cytometry in Oncology and Immunology Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By Offering
        • 9.3.3.2.4. By Application
        • 9.3.3.2.5. By End User

10. Middle East and Africa Flow Cytometry in Oncology and Immunology Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Technology
    • 10.2.3. By Offering
    • 10.2.4. By Application
    • 10.2.5. By End User
    • 10.2.6. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. UAE Flow Cytometry in Oncology and Immunology Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By Offering
        • 10.3.1.2.4. By Application
        • 10.3.1.2.5. By End User
    • 10.3.2. Saudi Arabia Flow Cytometry in Oncology and Immunology Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By Offering
        • 10.3.2.2.4. By Application
        • 10.3.2.2.5. By End User
    • 10.3.3. South Africa Flow Cytometry in Oncology and Immunology Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By Offering
        • 10.3.3.2.4. By Application
        • 10.3.3.2.5. By End User
    • 10.3.4. Turkey Flow Cytometry in Oncology and Immunology Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Type
        • 10.3.4.2.2. By Technology
        • 10.3.4.2.3. By Offering
        • 10.3.4.2.4. By Application
        • 10.3.4.2.5. By End User
    • 10.3.5. Egypt Flow Cytometry in Oncology and Immunology Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Type
        • 10.3.5.2.2. By Technology
        • 10.3.5.2.3. By Offering
        • 10.3.5.2.4. By Application
        • 10.3.5.2.5. By End User

11. Market Dynamics

  • 11.1. Drivers
    • 11.1.1. Rising Prevalence of Cancer Cases
    • 11.1.2. Advancement in Technology
    • 11.1.3. Recent Developments & Product Launches
  • 11.2. Challenges
    • 11.2.1. High Cost of the Products of the Flow Cytometry Equipment
    • 11.2.2. False antibody responses

12. Market Trends & Developments

13. Competitive Landscape

  • 13.1. Business Overview
  • 13.2. Product Offerings
  • 13.3. Recent Developments
  • 13.4. Financials (As Reported)
  • 13.5. Key Personnel
    • 13.5.1. Danaher Corporation
    • 13.5.2. Merck KGaA
    • 13.5.3. Miltenyi Biotec
    • 13.5.4. Neo-Genomics Laboratories, Inc.
    • 13.5.5. Thermo Fisher Scientific Inc
    • 13.5.6. Cell Signaling Technology, Inc
    • 13.5.7. Becton, Dickinson and Company
    • 13.5.8. Agilent Technologies, Inc.
    • 13.5.9. DiaSorin S.p.A (Luminex Corporation)
    • 13.5.10. OPKO Health, Inc.

14. Strategic Recommendations

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제